Beyond NPM-anaplastic lymphoma kinase driven lymphomagenesis: Alternative drivers in anaplastic large cell lymphoma

Current Opinion in Hematology

Volumn 20, Issue 4, 2013, Pages 374-381

  Tabbò, Fabrizio ^a   Ponzoni, Maurilio ^b   Rabadan, Raul ^c   Bertoni, Francesco ^d,e   Inghirami, Giorgio ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c Columbia University ^*  (United States)

^d INSTITUTE OF ONCOLOGY RESEARCH   (Switzerland)

^e ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

Author keywords

Anaplastic lymphoma kinase; Kinase inhibitors; Lymphoid differentiation; Mouse models; Signalling pathways

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; B LYMPHOCYTE INDUCED MATURATION PROTEIN 1; CCAAT ENHANCER BINDING PROTEIN BETA; CYCLIN D2; DNA METHYLTRANSFERASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 21; NOTCH1 RECEPTOR; NPM ANAPLASTIC LYMPHOMA KINASE; PROGRAMMED DEATH 1 LIGAND 1; PROTEIN P53; PROTEIN P63; SOMATOMEDIN; STAT3 PROTEIN; TRANSCRIPTION FACTOR AP 1; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG;

ALGORITHM; CELL PROLIFERATION; CELL TRANSFORMATION; CELL VIABILITY; CELLULAR DISTRIBUTION; CHROMOSOME TRANSLOCATION; CYTOTOXIC T LYMPHOCYTE; DEREGULATION; DIFFERENTIAL DIAGNOSIS; DIMERIZATION; DRUG INDUSTRY; DRUG RESPONSE; EMBRYO DEVELOPMENT; ENTEROPATHY ASSOCIATED T CELL LYMPHOMA; EXON; EXTRACELLULAR MATRIX; HUMAN; IN VITRO STUDY; LARGE CELL LYMPHOMA; NONHUMAN; ONCOGENE C MYC; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SOMATIC MUTATION;

CELL TRANSFORMATION, NEOPLASTIC; HUMANS; LYMPHOMA, LARGE-CELL, ANAPLASTIC; RECEPTOR PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION;

EID: 84880223497     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e3283623c07     Document Type: Review

References (49)

1. Swerdlow SH, Campo E, Haris NL, et al. WHO classification of tumors of haemotopoietic and lymphoid tissues. 4th ed. In: Swerdlow SH, Campo E, Haris NL, et al., editors. Lyon, France: International Agency for Research on Cancer; 2008. pp. 312-317.
2. Inghirami G, Pileri SA. Anaplastic large-cell lymphoma. Semin Diagn Pathol 2011; 28:190-201.
3. Rodriguez-Abreu D, Filho VB, Zucca E. Peripheral T-cell lymphomas, unspecified (or not otherwise specified): a review. Hematol Oncol 2008; 26:8-20.
4. Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 2008; 26:4124-4130.
5. Stein H, Mason DY, Gerdes J, et al. The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood 1985; 66:848-858.
6. Savage KJ, Harris NL, Vose JM, et al. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALKÃ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood 2008; 111:5496-5504.
7. Grewal JS, Smith LB, Winegarden JD 3rd, et al. Highly aggressive ALKpositive anaplastic large cell lymphoma with a leukemic phase and multiorgan involvement: a report of three cases and a review of the literature. Ann Hematol 2007; 86:499-508.
8. Zettl A, Rudiger T, Konrad MA, et al. Genomic profiling of peripheral T-cell lymphoma, unspecified, and anaplastic large T-cell lymphoma delineates novel recurrent chromosomal alterations. Am J Pathol 2004; 164:1837-1848.
9. Salaverria I, Beà S, Lopez-Guillermo A, et al. Genomic profiling reveals different genetic aberrations in systemic ALK-positive and ALK-negative anaplastic large cell lymphomas. Br J Haematol 2008; 140:516-526.
10. Boi M, Stathis A, Zucca E, et al. Genetic alterations in systemic nodal and extranodal noncutaneous lymphomas derived from mature T cells and natural killer cells. Cancer Sci 2012; 103:1397-1404.
11. Boi M, Rinaldi A, Piva R, et al. BLIMP1 is commonly inactivated in anaplastic large T-cell lymphomas (ALCL) [abstract]. Blood (ASH Annual Meeting Abstracts) 2011; 118:1131-1132.
12. Iwahara T, Fujimoto J, Wen D, et al. Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system. Oncogene 1997; 14:439-449.
13. Souttou B, Carvalho NB, Raulais D, Vigny M. Activation of anaplastic lymphoma kinase receptor tyrosine kinase induces neuronal differentiation through the mitogen-activated protein kinase pathway. J Biol Chem 2001; 276:9526-9531.
14. Mossé YP, Laudenslager M, Longo L, et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 2008; 455:930-935.
15. Morris SW, Kirstein MN, ValentineMB, et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 1994; 263:1281-1284.
16. Barreca A, Lasorsa E, Riera L, et al. Anaplastic lymphoma kinase in human cancer. J Mol Endocrinol 2011; 47:R11-R23.
17. Chiarle R, Voena C, Ambrogio C, et al. The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer 2008; 8:11-23.
18. Tabbò F, Barreca A, Piva R, Inghirami G. ALK signaling and target therapy in anaplastic large cell lymphoma. Front Oncol 2012; 2:41.
19. Soda M, Takada S, Takeuchi K, et al. A mouse model for EML4-ALK-positive lung cancer. Proc Natl Acad Sci USA 2008; 105:19893-19897.
20. Ott G, Katzenberger T, Siebert R, et al. Chromosomal abnormalities in nodal and extranodal CD30Ã anaplastic large cell lymphomas: infrequent detection of the t(2;5) in extranodal lymphomas. Genes Chromosomes Cancer 1998; 22:114-121.
21. Feldman AL, Dogan A, Smith DI, et al. Discovery of recurrent t(6;7)(p25.3;q32.3) translocations in ALK-negative anaplastic large cell lymphomas by massively parallel genomic sequencing. Blood 2011; 117:915- 919.
22. Vasmatzis G, Johnson SH, Knudson RA, et al. Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas. Blood 2012; 120:2280-2289. Using a high-throughput approach, the authors have identified novel structural abnormalities and discovered a putative pathogenetic role of TP53 and TP63 in ALCL.
23. Kuefer MU, Look AT, Pulford K, et al. Retrovirus-mediated gene transfer of NPM-ALK causes lymphoid malignancy in mice. Blood 1997; 90:2901-2910.
24. Bai RY, Dieter P, Peschel C, et al. Nucleophosmin-anaplastic lymphoma kinase of large-cell anaplastic lymphoma is a constitutively active tyrosine kinase that utilizes phospholipase C-gamma to mediate its mitogenicity. Mol Cell Biol 1998; 18:6951-6961.
25. Chiarle R, Gong JZ, Guasparri I, et al. NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors. Blood 2003; 101:1919-1927.
26. Turner SD, Alexander DR. What have we learnt from mouse models of NPMALK- induced lymphomagenesis? Leukemia 2005; 19:1128-1134.
27. Laimer D, Dolznig H, Kollmann K, et al. PDGFR blockade is a rational and effective therapy for NPM-ALK-driven lymphomas. Nat Med 2012; 18:1699-1704.
28. Zhang Q, Wang HY, Liu X, et al. IL-2R common gamma-chain is epigenetically silenced by nucleophosphin-anaplastic lymphoma kinase (NPM-ALK) and acts as a tumor suppressor by targeting NPM-ALK. Proc Natl Acad Sci USA 2011; 108:11977-11982.
29. Bonzheim I, Geissinger E, Roth S, et al. Anaplastic large cell lymphomas lack the expression of T-cell receptor molecules or molecules of proximal T-cell receptor signaling. Blood 2004; 104:3358-3360.
30. Ambrogio C, Martinengo C, Voena C, et al. NPM-ALK oncogenic tyrosine kinase controls T-cell identity by transcriptional regulation and epigenetic silencing in lymphoma cells. Cancer Res 2009; 69:8611-8619.
31. Zhang Q, Wang H, Kantekure K, et al. Oncogenic tyrosine kinase NPM-ALK induces expression of the growth-promoting receptor ICOS. Blood 2011; 118:3062-3071.
32. Marzec M, Zhang Q, Goradia A, et al. Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1). Proc Natl Acad Sci USA 2008; 105:20852-20857.
33. Dien Bard J, Gelebart P, Anand M, et al. IL-21 contributes to JAK3/STAT3 activation and promotes cell growth in ALK-positive anaplastic large cell lymphoma. Am J Pathol 2009; 175:825-834.
34. WuF, Wang P, Zhang J, et al. Studies of phosphoproteomic changes induced by nucleophosmin-anaplastic lymphoma kinase (ALK) highlight deregulation of tumor necrosis factor (TNF)/Fas/TNF-related apoptosis-induced ligand signaling pathway in ALK-positive anaplastic large cell lymphoma. Mol Cell Proteomics 2010; 9:1616-1632.
35. Marzec M, Liu X, Wong W, et al. Oncogenic kinase NPM/ALK induces expression of HIF1alpha mRNA. Oncogene 2010; 30:1372-1378.
36. Dejean E, Renalier MH, Foisseau M, et al. Hypoxia-microRNA-16 downregulation induces VEGF expression in anaplastic lymphoma kinase (ALK)- positive anaplastic large-cell lymphomas. Leukemia 2011; 25:1882- 1890.
37. Merkel O, Hamacher F, Laimer D, et al. Identification of differential and functionally active miRNAs in both anaplastic lymphoma kinase (ALK)Ã and ALK- anaplastic large-cell lymphoma. Proc Natl Acad Sci USA 2010; 107:16228-16233.
38. Ambrogio C, Voena C, Manazza AD, et al. The anaplastic lymphoma kinase controls cell shape and growth of anaplastic large cell lymphoma through Cdc42 activation. Cancer Res 2008; 68:8899-8907.
39. Colomba A, Giuriato S, Dejean E, et al. Inhibition of Rac controls NPM-ALKdependent lymphoma development and dissemination. Blood Cancer 2011; 1:e2.
40. Dupuis-Coronas S, Lagarrigue F, Ramel D, et al. The nucleophosmin- anaplastic lymphoma kinase oncogene interacts, activates, and uses the kinase PIKfyve to increase invasiveness. J Biol Chem 2011; 286:32105-32114.
41. Zhang J, Wang P, Wu F, et al. Aberrant expression of the transcriptional factor Twist1 promotes invasiveness in ALK-positive anaplastic large cell lymphoma. Cell Signal 2012; 24:852-858.
42. Fornari A, Piva R, Chiarle R, et al. Anaplastic large cell lymphoma: one or more entities among T-cell lymphoma? Hematol Oncol 2009; 27:161-170.
43. Barry TS, Jaffe ES, Sorbara L, et al. Peripheral T-cell lymphomas expressing CD30 and CD15. Am J Surg Pathol 2003; 27:1513-1522.
44. Gorczyca W, Tsang P, Liu Z, et al. CD30-positive T-cell lymphomas coexpressing CD15: an immunohistochemical analysis. Int J Oncol 2003; 22:319-324.
45. Piva R, Agnelli L, Pellegrino E, et al. Gene expression profiling uncovers molecular classifiers for the recognition of anaplastic large-cell lymphoma within peripheral T-cell neoplasms. J Clin Oncol 2010; 28:1583-1590.
46. Agnelli L, Mereu E, Pellegrino E, et al. Identification of a 3-gene model as a powerful diagnostic tool for the recognition of ALK-negative anaplastic largecell lymphoma. Blood 2012; 120:1274-1281.
47. Garber K. From human to mouse and back: 'tumorgraft' models surge in popularity. J Natl Cancer Inst 2009; 101:6-8.
48. Shultz LD, Ishikawa F, Greiner DL. Humanized mice in translational biomedical research. Nat Rev Immunol 2007; 7:118-130.
49. Tabbò F, Barreca A, Machiorlatti R, et al. Humanized NOD/Scid/IL2g-/- tumorgrafts recapitulate primary anaplastic large cell lymphoma [abstract]. American Association for Cancer Research Annual Meeting, April 6-10 2013, Washington, DC 2013; 463.